Novo Nordisk (NOVOB.DK) shares are gaining 3.0% after the company raised its sales forecast for 2023 on strong demand for Ozempic and Wegovy medicines.
- Operating profit at constant exchange rates +40% to +46%, previously expected +31% to +37%, Bloomberg estimated +37.5%
- Sales at constant exchange rates +32% to +38%, previously expected +27% to +33%, Bloomberg estimated +31.7%.
US OPEN: Falling oil prices drive risk appetite up! Nasdaq leads rebound (25.08.2026)
Market Wrap: Cautious rebound in Europe after the drop in oil prices
Nvidia Goes to Space. SpaceX Is Building Satellites Powered by Its Chips
Morning Wrap: Strong Crypto, Weaker Nasdaq and Another Chapter in the US–Canada Trade War